Argent BioPharma Acquires AusCann Group's Key Assets

August 28, 2025
Argent BioPharma Ltd. has signed a binding term sheet to acquire the core assets and intellectual property of AusCann Group Holdings Ltd., enhancing its clinical pipeline and European presence.

Argent BioPharma Ltd. has signed a binding term sheet to acquire the core assets and intellectual property of AusCann Group Holdings Ltd., announced in a press release. This acquisition includes the Neuvis® drug delivery platform, FDA-facing epilepsy pre-clinical data, and EU-GMP manufacturing capabilities.

The USD 15 million share-based transaction is set to strengthen Argent's lead programs, CannEpil® and CimetrA®, while expanding its European footprint. The acquisition also adds significant audited assets, enhancing Argent's net stockholders' equity and supporting its planned dual U.S. national exchange listing.

As part of the acquisition, Mr. Andrew Chapman will join Argent's Board as Executive Director, bringing expertise in capital markets and biotech. The transaction is expected to complete in Q3 2025, subject to customary closing conditions, with integration planning already underway.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

08/29
IQSTEL Partners with Mobility Tech for AI Call Center Solutions
08/29
OPTEL Group Acquires Vanguard Robotics to Boost Pharma Automation
08/28
Fujitsu Unveils AI Agent Platform for Healthcare Efficiency
08/28
BranchLab Appoints Dan Parkes as CTO
08/28
MedaSync Gains Strategic Investment from Omega Healthcare

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Governing the Future: A Strategic Framework for AI Adoption in Financial Institutions

This whitepaper explores the transformative impact of artificial intelligence on the financial industry, focusing on the governance challenges and regulatory demands faced by banks. It provides a strategic framework for AI adoption, emphasizing the importance of a unified AI approach to streamline compliance and reduce operational costs. The document offers actionable insights and expert recommendations for banks with fewer than 2,000 employees to become leaders in compliant, customer-centric AI.

Read more

You May Also Like